| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP, Head of Research & Dev
1 company
Elizabeth H.Z. Thompson is EVP, Head of Research & Dev at ACAD. Elizabeth H.Z. Thompson's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $391K at current prices.
The ACAD filings lean toward selling, a net 19,993 shares.
Elizabeth H.Z. Thompson has 5 Form 4 filings on record from August 2024 to July 2026, all as EVP, Head of Research & Dev at ACADIA Pharmaceuticals (ACAD), 2024–2026.
The 11 reported transactions were 6 option or other derivative awards, 3 open-market sales and 2 option exercises.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $506K.
The largest open-market sale was 16,558 shares of ACAD at an average $26.13 on July 30, 2026, about $433K.
Neither of the two sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.